Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-FAP-RGD PET/CT : Dosimetry and Preliminary Clinical Translational Studies
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
As an new dual targeting PET radiotracer, 68Ga-FAP-RGD is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAP-RGD in patients with various types of cancer and compared them with the results of 68Ga-FAPI-02 or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAP-RGD.
Official title: 68Ga-FAP-RGD PET/CT : Dosimetry and Preliminary Clinical Translational Studies in Cancer Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2022-05-01
Completion Date
2025-10-01
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
68Ga-FAP-RGD
The dose will be 4-7mCi given intravenously.
68Ga-FAP-RGD
68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
Locations (1)
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China